Cipla launches skin treatment Daptomycin Injection in US

Drug firm Cipla on Wednesday said it has launched Daptomycin Injection, used for treating complicated skin infections, in the US market. Daptomycin Injection is generic version of Cubicin, Cipla said in a statement.

Also read:- Cipla employee settles case with SEBI, pays Rs 3 lakh

"Cipla and its subsidiary Cipla USA, Inc announce the launch of Daptomycin for Injection, 500mg/vial, single-dose vial, AP-rated generic equivalent of Cubicin for Injection in the US," the statement said.

Also read:- Cipla arm, Novartis enter agreement for Ultibro Breezhaler to treat COPD

According to IQVIA Health, Cubicin injection brand and generics had sales of around USD 606 million for the most recent 12 months ending in June 2019.

Also read:- Cipla API facility in Bengaluru gets EIR from USFDA

"The product is available for shipping immediately," the statement said.